Related Experiment Videos
[Angiotensin-converting enzyme inhibitors after AMI]
1Kardiologisk afdeling P, Amtssygehuset i Gentofte. ctp@heart.dk
Ugeskrift for Laeger
|October 6, 2001
Summary
Treatment with an ACE inhibitor significantly increased life expectancy by over 15 months in patients with left ventricular dysfunction post-myocardial infarction. This demonstrates a substantial survival benefit for this patient group.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Left ventricular dysfunction is a common complication following myocardial infarction.
- Reduced life expectancy is a significant concern for patients with post-myocardial infarction left ventricular dysfunction.
Purpose of the Study:
- To quantify the improvement in life expectancy associated with ACE inhibitor treatment in patients with left ventricular dysfunction after myocardial infarction.
- To evaluate the long-term survival benefit of trandolapril in this specific patient population.
Main Methods:
- The TRACE study prolonged follow-up to determine median lifetime in both placebo and treatment groups.
- Life expectancy was calculated as median lifetime.
- Patients received either placebo or an ACE inhibitor (trandolapril).
Main Results:
- Median lifetime was reached in the placebo group at 4.6 years.
- Trandolapril treatment increased median lifetime by 15.3 months (27% increase, 7-51% confidence interval).
Conclusions:
- ACE inhibitor therapy provides a substantial increase in life expectancy for patients with left ventricular dysfunction post-myocardial infarction.
- Trandolapril is an effective treatment for improving survival in this vulnerable patient group.